Trial reportJournal of cosmetic dermatology2025
Efficacy and Mechanism of Bazi Bushen Capsule on Skin Laxity: A Combination of Clinical and Network Pharmacology Study.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and Mechanism of Bazi Bushen Capsule on Skin Laxity: A Combination of Clinical and Network Pharmacology Study.Journal of cosmetic dermatology · 2025Trial
- Molecular mechanisms of traditional Chinese medicine in skin aging: a narrative review.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeThis study aims to explore the mechanism of Bazi Bushen Capsule (BZBS) in treating skin laxity by combining network pharmacology and clinical research.
methodsThe active ingredients and potential drug targets of BZBS were obtained from TCMSP, TCMBANK, and SuperTCM databases. The potential disease targets of skin laxity were obtained from GeneCards, OMIM, and DisGeNET databases. The common core targets and key compounds were determined using Cytoscape software to construct the Drug Key Compound-Target network and Protein-Protein Interaction network. The mechanism of BZBS in treating skin laxity was revealed by Gene Ontology and KEGG enrichment analysis. Subsequently, to further verify the analysis results, a prospective single-group clinical trial was conducted, including 35 female volunteers with skin laxity. The planned study visits were initially scheduled for a 12-week period. The volunteers' average depth of skin wrinkles, skin elasticity parameters, and skin moisture content were examined at 0 week before the experiment and 12 weeks after the experiment.
resultsNetwork pharmacology shows that key compounds are quercetin, kaempferol, arachidonate, suchilactone, ammidin, deoxyharringtonine, sitosterol, mandenol, ethyl linolenate, stigmasterol, poriferast-5-en-3beta-ol, and cholesterol; core targets include AKT1, IL6, TP53, TNF, EGFR, TGFB1, JUN, MMP9, MTOR, and MMP2; the Relaxin, MAPK, PI3K-Akt, JAK-STAT signaling pathways, and cellular senescence may be the main ways for BZBS in treating skin laxity. After BZBS treatment, the average wrinkling depth of the enrolled volunteers decreased, and the skin elasticity and moisture content increased.
conclusionBZBS may treat skin laxity by repairing the mucosal barrier, regulating protein metabolism, and showing good therapeutic effects.
trial registrationWHO-recognized clinical trial registry: ChiCTR2200058262.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.